Distinguished lecture: How was the world's biggest drug class discovered in Academia? - Professor Sir Marc Feldmann
- Lecture Theatre 2, School of Dentistry
- Medical and Dental Sciences
Register for this event
Attendance is CPD verifiable. Please email E.J.Malone@bham.ac.uk with any questions.
Sir Marc Feldmann is a Senior Research Fellow at Somerville, Oxford and Emeritus Professor at the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences at the University of Oxford. Sir Marc retired from directing Oxford’s Kennedy Institute of Rheumatology 2 years ago. He now divides his time between Oxford and New York City’s Mount Sinai Medical School. Sir Marc was one of the recipients of the 2014 Canada Gairdner International Awards, often seen as a predictor for the Nobel Prize for Medicine. He received his award alongside research colleague Sir Ravinder Nath Maini, a Visiting Professor at the Institute, “for the discovery of anti-TNF therapy for the treatment of rheumatoid arthritis and other inflammatory diseases”.
The aims and objectives of Marc’s lecture are to instil an understanding of:
1) Explain how TNF was identified as a target for therapy;
2) Explain how optimal use with methotrexate was defined;
3) Explain limitations;
4) Explain path towards greater efficacy
5) What’s coming up in the future?